Edward Fryar

Pacific GeneTech Ltd. is a biotech company based in Hong Kong, Hong Kong. Pacific GeneTech develops and commercializes next-generation vaccines and biologics for areas of high unmet or underserved needs in food safety and animal health. The Chinese company's proprietary "Aegis" vaccine platform combines cross-protective antigens and immunopotentiators in PGT vectors for broad-spectrum protection against multiple strains and species of infectious diseases. PGT has out-licensed its adjuvant for use in third-party vaccines and is developing broad applications for its adjuvant/delivery system. The private company's "Hercules" adjuvant/delivery system provides enhanced efficacy of inactivated and DNA vaccines, and its "Argo" yeast vector is a safe, flexible, and robust carrier of immunogenic material. PGT has out-licensed two of its leading poultry vaccines addressing economically important gastro-intestinal pathogens and has out-licensed its Hercules adjuvant for use in third-party vaccines. Vaccines for other pathogens and animal species are under development, including an experimental DNA vaccine for African swine fever. PGT is developing other applications for its Hercules adjuvant/delivery system and for the Argo vector. The company, through its affiliate company, PGTX, has commenced programs with collaborators addressing human dysentery and related diseases, and malaria. The company was founded in 2009, and the CEO is Tim Collard.

Pacific GeneTech Ltd. is a biotech company based in Hong Kong, Hong Kong. Pacific GeneTech develops and commercializes next-generation vaccines and biologics for areas of high unmet or underserved needs in food safety and animal health. The Chinese company's proprietary "Aegis" vaccine platform combines cross-protective antigens and immunopotentiators in PGT vectors for broad-spectrum protection against multiple strains and species of infectious diseases. PGT has out-licensed its adjuvant for use in third-party vaccines and is developing broad applications for its adjuvant/delivery system. The private company's "Hercules" adjuvant/delivery system provides enhanced efficacy of inactivated and DNA vaccines, and its "Argo" yeast vector is a safe, flexible, and robust carrier of immunogenic material. PGT has out-licensed two of its leading poultry vaccines addressing economically important gastro-intestinal pathogens and has out-licensed its Hercules adjuvant for use in third-party vaccines. Vaccines for other pathogens and animal species are under development, including an experimental DNA vaccine for African swine fever. PGT is developing other applications for its Hercules adjuvant/delivery system and for the Argo vector. The company, through its affiliate company, PGTX, has commenced programs with collaborators addressing human dysentery and related diseases, and malaria. The company was founded in 2009, and the CEO is Tim Collard.